↑ トップへ ← 戻る

 Drug(薬物リスト) DrugBank | All Description Patterns

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

211 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   ABX-464  4件: Abx464; Abx464 100mg; Abx464 25mg; Abx464 50mg;   -   -   -   3件:
46,
96,
97
 2   AZD-9056  2件: Azd9056; Azd9056 hydrochloride;   -   -   -   2件:
46,
96
 3   Abatacept  27件: Abatacept; Abatacept (aba); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept sc; Abatacept subcutaneous; Abatacept, rituximab or tocilizumab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Bms 188667 (abatacept); Decrease tocilizumab, abatacept; Double-blind abatacept; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept;   D03203   2件: CD80, CD86   12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis   24件:
11,
13,
19,
41,
44,
46,
49,
50,
51,
53,
55,
60,
65,
84,
93,
96,
97,
107,
164,
222,
271,
284,
285,
300
 4   Acetate  76件: 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate;   -   -   -   40件:
1,
2,
6,
10,
13,
35,
40,
46,
49,
51,
60,
64,
70,
71,
73,
75,
76,
78,
81,
83,
85,
86,
88,
90,
96,
97,
113,
145,
156,
162,
171,
206,
222,
224,
225,
235,
265,
288,
298,
299
 5   Acetylcysteine  8件: Acetylcysteine; Acetylcysteine sodium; Glatiramer acetate, n-acetylcysteine; N acetylcysteine; N-acetylcysteine; N-acetylcysteine (nac); N-acetylcysteine capsule; N-acetylcysteine, (nac);   D00221   -   -   16件:
6,
13,
19,
20,
49,
51,
58,
85,
94,
96,
97,
111,
164,
233,
298,
299
 6   Activated charcoal  -  D03251   -   -   8件:
6,
13,
46,
85,
86,
96,
97,
298
 7   Adalimumab  50件: Adalimumab; Adalimumab (40 mg); Adalimumab (ada); Adalimumab (d2e7); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab 40 mg; Adalimumab 40 mg eow or ew; Adalimumab 40 mg sc every other week; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab and infliximab; Adalimumab injection; Adalimumab injection [humira]; Adalimumab pfs and pen; Adalimumab prn; Adalimumab with methotrexate; Adalimumab, etanercept, golimumab or infliximab; Adalimumab-eu; Adalimumab-pfizer; Anti-tnf therapy (etanercept or adalimumab); Anti-tnf:adalimumab (subcutaneus); Application of adalimumab; Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar product to adalimumab; Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Double-blind adalimumab; Etanercept or adalimumab; Fitc-adalimumab; Gp2017 (adalimumab biosimilar); Humira (adalimumab); Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira® (adalimumab); Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Infliximab, etanercept, adalimumab; Methotrexate,adalimumab; New formulation adalimumab; Ol adalimumab 40 mg; Open-label adalimumab; Sb5 (proposed biosimilar to adalimumab); Start adalimumab in monotherapy; Tnf blockers (infliximab, adalimumab, etanercept); Treatment with adalimumab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);   D02597   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   15件:
19,
37,
41,
46,
56,
84,
96,
97,
151,
160,
164,
222,
226,
269,
271
 8   Ademetionine  -  D07128   -   -   15件:
6,
14,
22,
43,
44,
46,
47,
49,
50,
60,
84,
93,
96,
97,
172
 9   Albendazole  2件: Albendazole; Albendazole (eskazole);   D00134   -   -   1件:
96
 10   Alemtuzumab  18件: Alemtuzumab; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994); Alemtuzumab (campath ); Alemtuzumab (campath); Alemtuzumab (gz402673); Alemtuzumab 0.2 mg; Alemtuzumab 0.3 mg; Alemtuzumab 12 mg; Alemtuzumab 24 mg; Alemtuzumab and rituximab; Alemtuzumab gz402673; Alemtuzumab immunotherapy; Alemtuzumab injection [lemtrada]; Alemtuzumab, rituximab; Filgrastim, alemtuzumab; Transplant conditioning with mobilization and alemtuzumab; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan;   D02802   -   -   17件:
13,
15,
19,
20,
46,
49,
51,
60,
63,
65,
85,
96,
164,
234,
284,
285,
326
 11   Alfacalcidol  3件: Alendronate versus alfacalcidol (1-alpha oh vitamin d); Alfacalcidol; Ibandronate+alfacalcidol+calcium;   D01518   1件: VDR   4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   6件:
41,
46,
49,
50,
96,
235
 12   Alicaforsen  1件: Alicaforsen;   -   -   -   2件:
96,
97
 13   Allopurinol  4件: Allopurinol; Allopurinol sandoz 100 mg, tabletten; Allopurinol sodium; Azathioprine and allopurinol;   D00224   1件: XDH   5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism   6件:
6,
46,
57,
66,
96,
97
 14   Aminosalicylic Acid  8件: -aminosalicylic acid; 4-aminosalicylic acid; 4-aminosalicylic acid extended release granules; 5-aminosalicylic acid; 5-aminosalicylic acid (5-asa); 5-aminosalicylic acid(5-asa) and/or prednisone; Aminosalicylic acid; Mesalamine, 5-aminosalicylic acid;   D00162   -   -   2件:
96,
97
 15   Ammonium chloride  2件: Ammonium chloride; Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon;   D01139   -   -   1件:
96
 16   Amoxicillin  7件: Amoxicillin; Amoxicillin and tetracycline; Amoxicillin hydrate; Amoxicillin, metronidazole and tetracycline; Clartihromycin, amoxicillin, and omeprazole; Lansoprazole, amoxicillin, clarithromycin; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication);   D00229
 D02925
 D07452 
 -   -   6件:
6,
46,
63,
96,
97,
222
 17   Apixaban  2件: Apixaban; Apixaban 2.5 milligram;   D03213   1件: F10   1件: Complement and coagulation cascades   2件:
96,
97
 18   Ascorbic acid  4件: 2l polyethylene glycol/ascorbic acid; Ascorbic acid; Ascorbic acid (vitamin c); Ascorbic acid vit c;   D00018   -   -   13件:
10,
13,
49,
62,
86,
96,
97,
192,
206,
211,
212,
254,
284
 19   Atorvastatin  9件: Atorvastatin; Atorvastatin 10mg; Atorvastatin 20mg; Atorvastatin calcium; Atorvastatin tablet 20 mg; Interferon beta treatment to add-on atorvastatin treatment; Interferon beta-1b/atorvastatin group; Lisinopril, losartan, and atorvastatin; Untreated to atorvastatin treatment;   D00258
 D00887
 D07474 
 1件: HMGCR   4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   17件:
13,
46,
49,
51,
58,
63,
79,
84,
88,
93,
96,
160,
222,
225,
265,
271,
299
 20   Azathioprine  33件: 5-asa, prednisone, azathioprine or remicade; Azathioprine; Azathioprine (aza); Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine 25 mg; Azathioprine and allopurinol; Azathioprine in case of endoscopic recurrence; Azathioprine individualised dose; Azathioprine or 6-mercaptopurine; Azathioprine or adalimumab and infliximab; Azathioprine or mesalazine; Azathioprine or methotrexate; Azathioprine or mycophenolate mofetil; Azathioprine weight-based dose; Azathioprine+enteral nutrition; Azathioprine/prednisone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Continuation of azathioprine; Corticosteroid and azathioprine; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Early immunosuppressants (azathioprine, methotrexate); Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, azathioprine; Overencapsulated azathioprine (imuran) 50 mg tablet; Prednisone - azathioprine; Products containing azathioprine or 6-mercaptopurine; Rituximab (rtx) and azathioprine (aza); Steroids plus azathioprine;   D00238
 D03033 
 -   -   18件:
11,
13,
19,
35,
42,
43,
44,
45,
46,
49,
65,
66,
85,
94,
95,
96,
97,
162
 21   Azithromycin  10件: Azithromycin; Azithromycin (zitromax°); Azithromycin + metronidazole; Azithromycin + n-acetylcystein + inhaled corticosteroid; Azithromycin 250 mg tablets; Azithromycin 250mg capsule; Azithromycin 500 mg film-coated tablet; Azithromycin dihydrate; Po azithromycin; Study medication, azithromycin;   D02134
 D06390
 D07486 
 -   -   6件:
13,
84,
85,
96,
228,
299
 22   Bean  2件: Bean; Soya bean oil;   -   -   -   1件:
96
 23   Beta carotene  2件: Beta carotene; Beta carotene from dunaliella algae;   D03101   -   -   2件:
13,
96
 24   Betamethasone  6件: Betamethasone; Betamethasone acibutate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Intra-articular compound betamethasone; Intraarticular betamethasone; Phosphate and betamethasone acetate, 2 ml.;   D00244
 D00972
 D01357
 D01402
 D01637
 D02032
 D02286 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   6件:
2,
46,
65,
90,
96,
235
 25   Bifidobacterium longum infantis  -  -   -   -   2件:
96,
97
 26   Budesonide  39件: 0.5 mg budesonide effervescent tablet for orodispersible use; 1 mg budesonide effervescent tablet for orodispersible use; 1mg budesonide effervescent tablet for orodispersible use; 2mg budesonide effervescent tablet for orodispersible use; Budesonide; Budesonide ( zentacort capsules 3mg ); Budesonide (6 mg); Budesonide (9 mg); Budesonide 0.5mg orodispersible tablet twice daily; Budesonide 1mg orodispersible tablet twice daily; Budesonide 6 mg capsules, hard (bux-pvii prototype); Budesonide 9 mg capsules, hard (bux-pv); Budesonide 9 mg capsules, hard (bux-pvii prototype); Budesonide [0.4mg/ml] viscous suspension; Budesonide mmx 6 mg tablet; Budesonide mmx®; Budesonide mmx® 6 mg; Budesonide mmx® 9 mg; Budesonide oral suspension; Budesonide oral suspension [0.2 mg/ml]; Budesonide plus prevacid; Budesonide-formoterol single inhaler; Budesonide-mmx; Budesonide-mmx®; Budesonide-mmx® 6 mg; Budesonide-mmx® 9 mg; Budesonide-mmx™; Budesonide/formoterol; Combination oral budesonide and rectal hydrocortisone; Formoterol/budesonide; High dose of budesonide; Inhaled/swallowed budesonide; Methylprednisolone or budesonide; Oral budesonide; Oral budesonide suspension (mb-9); Oral budesonide suspension (obs); Oral viscous budesonide; Oral viscous budesonide (ovb); Viscous/swallowed budesonide;   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   10件:
66,
85,
93,
94,
95,
96,
97,
98,
228,
299
 27   Bupivacaine  8件: Bupivacaine; Bupivacaine & triamcinolone acetonide; Bupivacaine hydrochloride; Bupivacaine injection 0.5%; Bupivacaine/epinephrine/dexamethasone; Lap tap bupivacaine/epinephrine; Liposomal bupivacaine; Us tap bupivacaine/epinephrine;   D01450
 D07552 
 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A   3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction   7件:
46,
53,
70,
96,
168,
226,
298
 28   Bupropion  2件: Bupropion; Wellbutrin (bupropion);   D00817
 D07591
 D07938 
 2件: SLC6A2, SLC6A3   6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle   2件:
8,
96
 29   Caffeine  5件: Caffeine; Caffeine 100 mg; Caffeine 100-200 mg bid; Caffeine alkaloid; Dextromethorphan and caffeine;   D00528
 D01453 
 11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A   22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   6件:
2,
6,
46,
78,
96,
97
 30   Calcitriol  4件: Calcitriol; Calcitriol & calcium; Delayed release 6mp or calcitriol vs. purinethol; Rapamycin-calcitriol combination;   D00129   1件: VDR   4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   8件:
37,
46,
49,
66,
96,
158,
235,
326
 31   Calcium  25件: Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Rosuvastatin calcium; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium;   -   -   -   24件:
6,
13,
19,
46,
49,
51,
65,
68,
75,
79,
84,
93,
94,
95,
96,
97,
214,
215,
222,
224,
235,
265,
298,
299
 32   Calcium Carbonate  3件: Amorphous calcium carbonate; Calcium carbonate; Calcium carbonate and alphacalcidol;   D00932
 D10802 
 -   -   7件:
13,
19,
46,
75,
96,
235,
299
 33   Cannabidiol  6件: Cannabidiol; Cannabidiol (cbd); Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg;   D10915   2件: CNR1, CNR2   4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis   14件:
2,
6,
13,
46,
95,
96,
97,
140,
144,
145,
157,
158,
193,
271
 34   Carbonate ion  -  -   -   -   10件:
2,
13,
17,
19,
46,
75,
96,
127,
235,
299
 35   Celecoxib  7件: Celecoxib; Celecoxib (celebrex); Celecoxib 200 milligrams; Celecoxib 200mg capsule; Celecoxib 400 milligrams; Celecoxib, celebrex®; Fixed dose combination ciprofloxacin/celecoxib;   D00567   1件: PTGS2   20件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   9件:
2,
3,
34,
46,
70,
89,
96,
161,
271
 36   Certolizumab pegol  11件: 99mtc-s-hynic certolizumab pegol; Certolizumab pegol; Certolizumab pegol (cdp870); Certolizumab pegol (cdp870, tradename cimzia); Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg); Certolizumab pegol (czp); Certolizumab pegol (rinn); Certolizumab pegol + methotrexate (mtx); Certolizumab pegol 400 mg; Cimzia certolizumab pegol 200 mg/ml solution for injection; Infliximab, adalimumab, certolizumab pegol;   D03441   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   6件:
37,
46,
96,
97,
226,
271
 37   Chenodeoxycholic acid  1件: Chenodeoxycholic acid;   D00163   1件: NR1H4   1件: Bile secretion   4件:
20,
96,
234,
263
 38   Chloride ion  -  -   -   -   17件:
6,
11,
13,
14,
34,
46,
51,
96,
97,
127,
168,
193,
227,
228,
288,
297,
299
 39   Cholecalciferol  9件: 5000 iu of cholecalciferol; Calcium and cholecalciferol; Cholecalciferol; Cholecalciferol (vitamin d3); Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol and c. xanthorrhiza; Cholecalciferol concentrate; Cholecalciferol, vitamin d3;   D00188   1件: VDR   4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   15件:
6,
13,
19,
20,
34,
46,
49,
53,
60,
65,
96,
97,
228,
298,
299
 40   Chondroitin sulfate  4件: 2% sodium chondroitin sulfate; Chondroitin sulfate; Hyaluronic acid and chondroitin sulfate; Hyaluronic acid/chondroitin sulfate;   D00080   -   -   2件:
96,
226
 41   Ciprofloxacin  14件: Cipro (ciprofloxacin, bayq3939); Ciprofloxacin; Ciprofloxacin (cipro inhale, bayq3939); Ciprofloxacin (cipro, bayq3939); Ciprofloxacin (ciproxin); Ciprofloxacin dispersion for inhalation; Ciprofloxacin dpi; Ciprofloxacin for inhalation; Ciprofloxacin hydrochloride; Ciprofloxacin hydrochloride monohydrate; Fixed dose combination ciprofloxacin/celecoxib; Oral ciprofloxacin; Oral ciprofloxacin plus inhaled colistin; Po ciprofloxacin;   D00186
 D02216 
 -   -   5件:
2,
60,
96,
97,
299
 42   Clarithromycin  6件: Biaxin ( clarithromycin); Clarithromycin; Lansoprazole, amoxicillin, clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Rifabutin, clarithromycin, and clofazimine; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication);   D00276   -   -   8件:
6,
63,
84,
96,
97,
222,
228,
299
 43   Clazakizumab  1件: Clazakizumab;   D10312   -   -   2件:
46,
96
 44   Clofarabine  2件: Campath, busulfan, clofarabine; Clofarabine;   D03546   3件: POLA1, POLA2, RRM1   6件: DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   9件:
19,
20,
40,
46,
49,
60,
96,
234,
326
 45   Clofazimine  2件: Clofazimine; Rifabutin, clarithromycin, and clofazimine;   D00278   -   -   1件:
96
 46   Coenzyme M  -  -   -   -   9件:
13,
44,
45,
49,
51,
60,
65,
96,
164
 47   Colesevelam  2件: Colesevelam; Combination of fish oil and colesevelam;   D03582
 D07743 
 -   -   2件:
96,
260
 48   Curcumin  5件: Bio-enhanced curcumin soft gelatin capsule; Curcumin; Curcumin (longvida™); Curcumin supplement; Ifn beta 1 a + curcumin (bcm 95);   -   -   -   10件:
13,
46,
49,
67,
74,
94,
96,
97,
139,
299
 49   Cyanocobalamin  -  D00166
 D03615
 D03616
 D03617 
 -   -   12件:
6,
13,
49,
62,
86,
96,
97,
201,
229,
254,
284,
299
 50   Cyclophosphamide  48件: Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Busulfan, cyclophosphamide, atg, gcsf; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Campath, fludarabine, cyclophosphamide; Cyclophosphamide; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide (drug); Cyclophosphamide + pred; Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide 50mg; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and atg; Cyclophosphamide and steroids; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide monohydrate; Cyclophosphamide post transplant; Cyclophosphamide(ctx); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Cyclophosphamide-prednisone-azathioprine; Cyclophosphamide/glatiramer acetate; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; High-dose cyclophosphamide; Iv cyclophosphamide; Lenalidomide, dexamethasone and cyclophosphamide; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; Prednisone, cyclophosphamide; Rituximab and cyclophosphamide iv; Thalidomide, cyclophosphamide and prednisone;   D00287
 D07760 
 -   -   43件:
13,
14,
16,
19,
20,
26,
28,
35,
36,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
52,
56,
60,
61,
62,
65,
66,
84,
85,
93,
96,
162,
164,
172,
222,
224,
265,
274,
283,
284,
285,
288,
326,
331
 51   Denosumab  4件: Denosumab; Denosumab - immunoglobulin g2 human monoclonal antibody to rank ligand; Pralia 60 mg subcutaneous injection syringe(denosumab); Pralia 60mg subcutaneous injection syringe(denosumab);   D03684   1件: TNFSF11   7件: Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis   7件:
46,
50,
93,
95,
96,
274,
299
 52   Dexamethasone  35件: Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Bupivacaine/epinephrine/dexamethasone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Control intervention (no dexamethasone); Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Dexamethasone; Dexamethasone (1 cycle); Dexamethasone (4 cycles); Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0,5mg; Dexamethasone 0.5mg tablet; Dexamethasone 21-phosphate; Dexamethasone 2mg tablets; Dexamethasone abcur; Dexamethasone and rituximab; Dexamethasone parotid irrigation; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dexamethasone sodium phosphate 250 mg/10 ml solution; Dexamethasone sodium phosphate ph. eur.; Dexamethasone soduim phosphate; Dexamethasone, 40 mg; High dose dexamethasone pulses; Intraarticular dexamethasone; Intravenous dexamethasone 1 mg; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Lenalidomide, dexamethasone and cyclophosphamide; Melphalan, thalidomide and dexamethasone; Mmf and dexamethasone; Peri-neural dexamethasone 1 mg; Pomalidomide and dexamethasone;   D00292
 D00975
 D01510
 D01615
 D01632
 D01948
 D02174
 D02591
 D02592 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   20件:
13,
16,
28,
35,
46,
53,
63,
65,
70,
74,
75,
81,
83,
84,
90,
96,
97,
222,
296,
299
 53   Dextran  4件: Dextran; Dextran sulfate sodium; Iron dextran; Iron(iii)- hydroxide dextran complex;   D00060   -   -   5件:
2,
62,
79,
96,
97
 54   Dextromethorphan  9件: Dextromethorphan; Dextromethorphan 30 mg; Dextromethorphan and caffeine; Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Dimebon + dextromethorphan;   D00848
 D03742
 D03744 
 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D   17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway   9件:
2,
6,
8,
13,
46,
78,
96,
97,
156
 55   Dimethicone  -  D01540   -   -   2件:
13,
96
 56   Docusate  -  D00305   -   -   7件:
13,
62,
86,
96,
97,
254,
284
 57   Doxycycline  7件: Antimicrobial therapy: co-trimoxazole or doxycycline; Doxycycline; Doxycycline 100 mg capsules; Doxycycline hyclate; Doxycycline hyclate ph.eur; Interferon beta 1a, oral doxycycline; Treatment with systemic therapy (doxycycline);   D00307
 D02129
 D03903
 D03904
 D07876 
 -   -   15件:
13,
23,
28,
46,
84,
85,
89,
96,
97,
158,
162,
167,
227,
280,
299
 58   Efalizumab  1件: Efalizumab;   D03959   1件: ITGAL   11件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis   9件:
11,
13,
37,
46,
49,
53,
61,
95,
96
 59   Entecavir  1件: Entecavir;   D04008
 D07896 
 -   -   5件:
46,
56,
96,
97,
271
 60   Epinephrine  4件: Bupivacaine/epinephrine/dexamethasone; Epinephrine; Lap tap bupivacaine/epinephrine; Us tap bupivacaine/epinephrine;   D00095
 D00996
 D02149 
 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3   13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   9件:
6,
13,
46,
86,
96,
168,
226,
231,
256
 61   Ergocalciferol  2件: Ergocalciferol; Ergocalciferol (vitamin d2);   D00187   1件: VDR   4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   5件:
46,
84,
96,
97,
299
 62   Erythropoietin  4件: Erythropoietin; Erythropoietin human recombinant (eporh); Recombinant human erythropoietin; Recombinant human erythropoietin(rhepo);   D03231   1件: EPOR   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   9件:
2,
6,
13,
22,
46,
47,
70,
95,
96
 63   Ethanol  7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel;   D00068
 D02798
 D04855
 D06542 
 -   -   49件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 64   Etiprednol dicloacetate  1件: Etiprednol dicloacetate;   D04100   -   -   1件:
96
 65   Etrolizumab  1件: Etrolizumab;   D09901   1件: ITGB7   11件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer   2件:
96,
97
 66   Everolimus  6件: Afinitor (everolimus); Everolimus; Everolimus (rad001); Everolimus (rad001) , afinitor®; Rad001, everolimus; Rad001: everolimus;   D02714   1件: MTOR   43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   9件:
34,
67,
89,
96,
137,
157,
158,
228,
277
 67   Ferric carboxymaltose  2件: Ferric carboxymaltose; Intravenous administration of ferric carboxymaltose;   D08920   -   -   4件:
86,
96,
97,
299
 68   Filgotinib  4件: Filgotinib; Inn - filgotinib; Proposed inn - filgotinib; Propsoed inn - filgotinib;   D10871   1件: JAK1   26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis   6件:
46,
53,
96,
97,
222,
271
 69   Filgrastim  6件: Ep2006 (filgrastim); Filgrastim; Filgrastim (g-csf); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim);   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   28件:
2,
6,
13,
16,
25,
26,
28,
34,
35,
36,
40,
41,
42,
45,
46,
49,
51,
60,
62,
65,
85,
96,
113,
164,
283,
284,
285,
331
 70   Fish oil  10件: Combination fish oil and borage seed oil; Combination of fish oil and colesevelam; Fish oil; Fish oil concentrate; Fish oil supplement; Fish oil, gamma-linolenic acid; Fish oil, rich in omega-3-acids; Fish oil,rich in omega 3 acids; Lipoic acid (la) with fish oil and la without fish oil; Omega-3 fatty acid fish oil supplement;   -   -   -   7件:
13,
46,
49,
66,
96,
260,
299
 71   Fluconazole  1件: Fluconazole;   D00322
 D01429 
 -   -   1件:
96
 72   Fludarabine  23件: Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine and atg; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Busulfan, fludarabine, atg, tli; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Campath, fludarabine, cyclophosphamide; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Fludarabine; Fludarabine (flu); Fludarabine monophosphate; Fludarabine phosphate; Fludarabine phosphate 30 mg; Fludarabine phosphate 40 mg; Fludarabine, busulfan, thymoglobulin; Fludarabine, cyclophosphamide; Fludarabine, melphalan, thiotepa; Fludarabine/ melphalan; Fludarabine/busulfan; Sq fludarabine; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan;   D01907
 D07966 
 1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   17件:
13,
28,
36,
46,
49,
51,
60,
61,
62,
65,
85,
96,
164,
283,
284,
285,
326
 73   Fluorine F-18  1件: Fluorine f 18;   D05860   -   -   4件:
40,
46,
49,
96
 74   Folic acid  5件: Folic acid; Folic acid or folate; Folic acid, vitamin b6, vitamin b12; Methotrexate and folic acid; Rituximab, mtx, folic acid;   D00070   -   -   11件:
6,
13,
46,
49,
62,
84,
86,
96,
97,
254,
284
 75   Fosfomycin  1件: Fosfomycin;   D00925
 D02187
 D02188
 D04253 
 -   -   2件:
96,
97
 76   GLPG-1205  1件: Glpg1205;   -   -   -   3件:
85,
96,
97
 77   Glatiramer  23件: 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; Cyclophosphamide/glatiramer acetate; Experimental glatiramer acetate; Glatiramer; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Human interferon beta-1a and glatiramer acetate;   D04318   20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G   32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis   4件:
2,
13,
96,
156
 78   Golimumab  36件: Adalimumab, etanercept, golimumab or infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Exposure to golimumab; Golimumab; Golimumab (cnto 148); Golimumab (glm); Golimumab (optimization); Golimumab 1 mg per kg; Golimumab 100 mg; Golimumab 100 mg injections; Golimumab 2 mg per kg; Golimumab 2 mg/kg iv; Golimumab 200 mg; Golimumab 4 mg per kg; Golimumab 400 mg; Golimumab 50 mg; Golimumab 50 mg in patients <80 kg and golimumab 100 mg in patients >80 kg; Golimumab 50 mg injections; Golimumab dose 1; Golimumab dose 2; Golimumab final vialed product (fvp); Golimumab injection; Golimumab intravenous; Golimumab intravenous (iv); Golimumab liquid in prefilled pen; Golimumab liquid in prefilled syringe; Golimumab liquid in vial; Golimumab pre-filled syringe; Golimumab prefilled syringe; Golimumab treatment optimization.; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Iv golimumab; Sc golimumab; Simponi (golimumab); Simponi® (golimumab); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);   D04358   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   5件:
46,
84,
96,
97,
271
 79   Green tea leaf  1件: Green tea leaf;   D06903   -   -   5件:
6,
17,
28,
46,
96
 80   Guselkumab  4件: Guselkumab; Guselkumab 100 mg; Guselkumab dose 1; Guselkumab dose 2;   D10438   1件: IL23A   9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis   3件:
37,
96,
97
 81   Hepatitis A Vaccine  3件: Epaxal berna (virosomal hepatitis a vaccine); Hepatitis a vaccine; Hepatitis a vaccine and tetanus vaccine;   -   -   -   3件:
46,
96,
97
 82   Human Serum Albumin  4件: Human serum albumin; Human serum albumin (hsa) fused to recombinant human growth hormone (hgh); Human serum albumin (hsa) fused to somatropin; Recombinant human serum albumin (hsa) fused to human growth hormone (hgh);   D05424   -   -   3件:
2,
78,
96
 83   Human interferon beta  6件: Human interferon beta; Human interferon beta 1a (rebif); Human interferon beta-1a and glatiramer acetate; New formulation of rebif - human interferon beta-1a; Recombinant human interferon beta; Recombinant human interferon beta-1a;   -   -   -   6件:
13,
14,
20,
26,
96,
97
 84   Human interleukin-2  2件: Human interleukin-2; Recombinant human interleukin-2 (rhil-2);   -   -   -   14件:
2,
13,
35,
46,
49,
51,
55,
56,
63,
65,
95,
96,
97,
271
 85   Hydroxide ion  -  -   -   -   4件:
46,
96,
97,
284
 86   Hydroxychloroquine  16件: Hydroxychloroquine; Hydroxychloroquine (z0188); Hydroxychloroquine + prednisone; Hydroxychloroquine high; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Hydroxychloroquine sulfate; Hydroxychloroquine sulphate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sirolimus and hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Versus hydroxychloroquine;   D08050   -   -   18件:
13,
41,
46,
48,
49,
53,
56,
66,
84,
89,
90,
96,
222,
234,
254,
271,
298,
299
 87   Hydroxyethyl Starch  -  D03335   -   -   2件:
96,
97
 88   Icosapent  -  D08061   -   -   5件:
49,
96,
97,
296,
297
 89   Infliximab  66件: 99m technetium infliximab; 99mtc-infliximab; Abp 710 - biosimilar to infliximab; Adalimumab and infliximab; Adalimumab, etanercept, golimumab or infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Ct-p13 sc (infliximab); Cyclosporine vs infliximab; Inflectra (infliximab); Infliximab; Infliximab (bcd-055); Infliximab (ifx alone); Infliximab (ifx); Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 20 mg/kg; Infliximab 3 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab and mtx; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-biosimilar; Infliximab-eu; Infliximab-innovator; Infliximab-pfizer; Innovator infliximab; Intravitreal infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remicaide (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Topical infliximab; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);   D02598   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   23件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 90   Inositol  1件: Inositol;   D08079   -   -   2件:
96,
97
 91   Insulin Human  -  D00085
 D03230 
 1件: INSR   20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway   2件:
96,
156
 92   Interferon alfa  5件: Interferon alfa; Interferon alfa-2a; Interferon alfa-2b; Pegylated interferon alfa; Recombinant interferon alfa;   D03305   2件: IFNAR1, IFNAR2   17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway   5件:
25,
26,
28,
56,
96
 93   Interferon beta-1a  28件: Avonex (interferon beta 1a); Avonex (interferon beta-1a), biogen idec ltd; Bcd-033 (interferon beta 1a); Bg9418 (interferon beta-1a); Human interferon beta 1a (rebif); Human interferon beta-1a and glatiramer acetate; Interferon beta 1a; Interferon beta 1a 30 ug im once weekly; Interferon beta 1a, oral doxycycline; Interferon beta-1a; Interferon beta-1a (avonex); Interferon beta-1a (avonex®); Interferon beta-1a (current approved manufacturing process invloving fbs); Interferon beta-1a (new process, manufactured without fbs); Interferon beta-1a (rebif); Interferon beta-1a 30 µg; Interferon beta-1a fbs-free/hsa-free, rnf; Interferon beta-1a hsa+ biosimilar; Interferon beta-1a hsa-free biosimilar; Interferon beta-1a original; Interferon beta1a; New formulation of rebif - human interferon beta-1a; Pegylated interferon beta-1a; Rebif (interferon beta 1a); Rebif (interferon beta-1a); Rebif (interferon beta-1a), merck serono europe ltd; Recombinant human interferon beta-1a; Sc interferon beta-1a;   D04554   2件: IFNAR1, IFNAR2   17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway   5件:
13,
14,
26,
96,
97
 94   Inulin  2件: Inulin; Oligofructose enriched inulin;   D00171   -   -   2件:
96,
299
 95   Iron  14件: Injection of iron; Iron; Iron chelating agents; Iron dextran; Iron oxide; Iron sucrose; Iron sulphate; Iron sulphate 200mg coated tablets; Iron supplement; Iron supplement 300-600 mg/day; Iron(iii)- hydroxide dextran complex; Oral iron; Ultra small particles of iron oxide (uspio); Ultrasmall particles of iron oxide;   -   -   -   7件:
13,
62,
86,
96,
97,
254,
284
 96   Iron saccharate  -  -   -   -   3件:
62,
96,
97
 97   Isopropyl alcohol  -  D00137   -   -   10件:
13,
46,
58,
84,
96,
97,
269,
271,
279,
298
 98   JNJ-40346527  5件: Jnj-40346527; Jnj-40346527-aac; Jnj-40346527-aac - capsule - 50 mg; Prv-6527 (jnj-40346527); Prv-6527(jnj-40346527);   -   -   -   2件:
46,
96
 99   Kanamycin  1件: Kanamycin;   D00866
 D03262
 D07497 
 -   -   2件:
96,
291
 100   L-Glutamine  1件: L-glutamine;   D00015   -   -   6件:
87,
96,
97,
113,
245,
299
 101   L-Threonine  2件: L-lysyl-d-prolyl-l-threonine acetate; L-threonine;   D00041   -   -   3件:
86,
96,
97
 102   Lactulose  3件: High dose lactulose; Lactulose; Lactulose/rhamnose solution;   D00352   -   -   2件:
96,
291
 103   Laquinimod  8件: Laquinimod; Laquinimod 0.6; Laquinimod 1.2; Laquinimod capsules 0.3 mg; Laquinimod capsules 0.6 mg; Laquinimod cápsulas 0.5 mg; Laquinimod sodium (usan); Laquinimod tablets 0.3 mg;   -   -   -   4件:
8,
13,
49,
96
 104   Lenalidomide  5件: Lenalidomide; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Lenalidomide, dexamethasone and cyclophosphamide;   D04687   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   8件:
16,
26,
28,
34,
49,
96,
284,
300
 105   Levocarnitine  4件: Levocarnitine; Levocarnitine propyl hydrochloride; Valproate, levocarnitine; Valproic acid and levocarnitine;   D02030
 D02176
 D04713 
 -   -   10件:
3,
5,
13,
53,
58,
96,
97,
265,
298,
316
 106   Losartan  8件: Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan bluefish 50 mg; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Sildenafil and losartan;   D00357
 D08146 
 1件: AGTR1   14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   18件:
13,
17,
19,
46,
58,
66,
67,
85,
96,
97,
98,
113,
164,
167,
179,
215,
222,
299
 107   Maltodextrin  3件: Maltodextrin; Maltodextrin fiber supplement; Resistant maltodextrin;   D02329   -   -   4件:
6,
13,
96,
97
 108   Maltose  2件: Ferric carboxy maltose; Maltose;   D00044   -   -   2件:
96,
97
 109   Mannitol  7件: Dp mannitol; Idpm: inhaled dry powder mannitol; Inhaled dry powder mannitol; Inhaled mannitol; Mannitol; Mannitol + pulmozyme; Mannitol inhalation powder;   D00062   -   -   3件:
6,
96,
299
 110   Masitinib  10件: Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib (ab1010); Masitinib 100mg; Masitinib 200mg; Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate;   D10229   1件: KIT   11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway   6件:
2,
5,
6,
13,
46,
96
 111   Mecasermin  2件: Mecasermin; Mecasermin [rdna origin] 10mg/ml solution;   D03297
 D04870 
 2件: GHR, IGF1R   33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway   6件:
65,
78,
96,
168,
265,
299
 112   Medical Cannabis  -  -   -   -   6件:
2,
6,
13,
90,
96,
97
 113   Medium-chain triglycerides  -  -   -   -   2件:
96,
318
 114   Melphalan  8件: Carmustine, etoposide, cytarabine, and melphalan (beam); Fludarabine, melphalan, thiotepa; Fludarabine/ melphalan; Melphalan; Melphalan hydrochloride; Melphalan, thalidomide and dexamethasone; Propylene glycol-free melphalan hydrochloride; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan;   D00369   -   -   14件:
11,
13,
14,
19,
20,
28,
60,
62,
65,
96,
164,
234,
284,
285
 115   Mercaptopurine  8件: 6 mercaptopurine; 6-mercaptopurine; Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine or 6-mercaptopurine; Delayed release 6 mercaptopurine; Mercaptopurine; Mercaptopurine (puri-nethol); Products containing azathioprine or 6-mercaptopurine;   D00161
 D04931 
 1件: HPRT1   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   5件:
86,
94,
96,
97,
164
 116   Mesalazine  27件: 1500mg mesalazine pellets; 250mg mesalazine pellets; 500mg mesalazine pellets; 750mg mesalazine pellets; Azathioprine or mesalazine; Mesalazine; Mesalazine (3,600 mg); Mesalazine (mesalamine); Mesalazine - tid 1000 mg; Mesalazine - tid 2x 500 mg; Mesalazine 1000 mg gastro-resistant tablets; Mesalazine 250mg; Mesalazine 250mg tablet and nitazoxanide 500mg oral tablet; Mesalazine 4g enema; Mesalazine 500 mg gastro-resistant tablets (salofalk® 500 mg); Mesalazine ec 500 mg; Mesalazine enema; Mesalazine sustained-release tablets; Mesalazine tablet; Mesalazine tablets; Mesalazine with hydrocortisone sodium succinate; Mesalazine, tripterygium glycosides; Mmx mesalamine/mesalazine; Mmx mesalamine/mesalazine (high dose); Mmx mesalamine/mesalazine (low dose); Overencapsulated mesalazine tablets; Spd476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine;   D00377   -   -   4件:
46,
96,
97,
164
 117   Methacholine  1件: Methacholine;   -   -   -   1件:
96
 118   Methotrexate  81件: Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Azathioprine or methotrexate; Bms-582949 and methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Certolizumab pegol + methotrexate (mtx); Clobetasol propionate + methotrexate; Cp-690,550 + methotrexate; Cyclosporin, methotrexate (gvhd prophylaxis); Early immunosuppressants (azathioprine, methotrexate); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept, methotrexate, prednisolone; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Intrathecal methotrexate; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 25 mg; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate and folic acid; Methotrexate as methotrexate disodium; Methotrexate bellon; Methotrexate bellon 25mg/ml; Methotrexate capsules; Methotrexate disodium; Methotrexate lachema 5inj. sol; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate treatment; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Mycophenolate mofetil,methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Treatment with systemic therapy (methotrexate); Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level;   D00142
 D02115 
 2件: DHFR, DHFR2   4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331
 119   Methoxsalen  2件: Methoxsalen; Methoxsalen +ecp;   D00139   -   -   3件:
36,
46,
96
 120   Methylprednisolone  29件: Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides;   D00407
 D00751
 D00979
 D05000
 D05001
 D05002 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296
 121   Metronidazole  6件: 10% metronidazole ointment; Amoxicillin, metronidazole and tetracycline; Azithromycin + metronidazole; Metronidazole; Metronidazole capsule 50 mg; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication);   D00409
 D05016
 D05017 
 -   -   8件:
46,
51,
63,
94,
95,
96,
97,
291
 122   Midazolam  6件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Midazolam; Midazolam 2 mg; Midazolam 3 mg; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; S-ketamine & midazolam;   D00550
 D00696
 D05028 
 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction   10件:
2,
3,
6,
13,
46,
70,
96,
97,
231,
298
 123   Mirikizumab  1件: Mirikizumab;   D11123   1件: IL23A   9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis   2件:
96,
97
 124   Mongersen  1件: Mongersen;   D10956   1件: SMAD7   2件: Hippo signaling pathway, TGF-beta signaling pathway   2件:
96,
97
 125   Mosapride  1件: Mosapride;   D08236   1件: HTR4   4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway   1件:
96
 126   Muromonab  2件: Muromonab; Muromonab-cd3;   D05092   3件: CD3D, CD3E, CD3G   11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   3件:
60,
96,
97
 127   Mycophenolate mofetil  17件: Azathioprine or mycophenolate mofetil; Cellcept (mycophenolate mofetil); Cyclosporine combine with mycophenolate mofetil; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Mycophenolate mofetil; Mycophenolate mofetil (cellcept); Mycophenolate mofetil (mmf); Mycophenolate mofetil (mmf) 3 g/day; Mycophenolate mofetil 2 g/day; Mycophenolate mofetil [cellcept]; Mycophenolate mofetil orally 1000 mg twice a day (bid); Mycophenolate mofetil plus lower dose of prednisone; Mycophenolate mofetil(mmf); Mycophenolate mofetil, low dose steroid; Mycophenolate mofetil,methotrexate; Prednisolone and mycophenolate mofetil; Prednisone and mycophenolate mofetil;   D00752
 D05094
 D05095 
 2件: IMPDH1, IMPDH2   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   32件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
85,
95,
96,
162,
164,
222,
224,
226,
234,
283,
284,
285,
300
 128   Mycophenolic acid  2件: Mycophenolic acid; Mycophenolic acid mofetil;   D05096   2件: IMPDH1, IMPDH2   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   34件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
84,
85,
95,
96,
162,
164,
222,
224,
226,
228,
234,
283,
284,
285,
300
 129   Naltrexone  5件: 4.5 mg naltrexone; Low dose naltrexone; Naltrexone; Naltrexone hydrochloride; Naltrexone-hcl;   D02095
 D05113 
 3件: OPRD1, OPRK1, OPRM1   5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway   11件:
6,
10,
13,
40,
41,
42,
43,
44,
45,
96,
97
 130   Natalizumab  12件: Bg00002 (natalizumab); Bg00002-e (natalizumab high titer); Bg0002 (natalizumab); Natalizumab; Natalizumab (bg00002); Natalizumab (ntz); Natalizumab (tysabri); Natalizumab for iv infusion; Natalizumab for subcutaneous injection; Natalizumab treatment; Tysabri ® (natalizumab); Tysabri® (natalizumab);   D06886   1件: ITGA4   14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection   6件:
13,
15,
25,
46,
63,
96
 131   Neomycin  1件: Neomycin;   D08260   -   -   4件:
96,
97,
296,
299
 132   Nitazoxanide  3件: Mesalazine 250mg tablet and nitazoxanide 500mg oral tablet; Nitazoxanide; Nitazoxanide 500mg oral tablet;   D02486   -   -   2件:
96,
97
 133   Nivolumab  1件: Nivolumab;   D10316   1件: PDCD1   3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway   10件:
13,
26,
41,
46,
49,
50,
51,
53,
96,
97
 134   Octreotide  5件: Gallium-68-dota-n-octreotide; Octreotide; Octreotide lar; Octreotide lar / sandostatin lar (lar=long acting release); Octreotide-lar;   D00442
 D06495 
 1件: SSTR2   4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway   8件:
67,
75,
84,
85,
89,
96,
193,
227
 135   Olive oil  2件: Freshly-pressed extra virgin olive oil; Olive oil;   D03311   -   -   4件:
13,
49,
53,
96
 136   Olokizumab  10件: Olokizumab; Olokizumab 120 mg; Olokizumab 240 mg; Olokizumab 60 mg; Olokizumab 64 mg sc q2w; Olokizumab 64 mg sc q4w; Olokizumab 64mg q2w; Olokizumab 64mg q4w; Olokizumab q2w; Olokizumab q4w;   -   -   -   2件:
46,
96
 137   Omega-3 fatty acids  6件: Dietary supplement omega3 fatty acids aand vitamins; Lipoic acid and omega-3 fatty acids; Omega 3 fatty acids; Omega-3 fatty acids; Omega3 fatty acids; Triomar™ (omega-3 fatty acids);   -   -   -   7件:
13,
46,
49,
66,
79,
96,
299
 138   Omega-3-carboxylic acids  -  -   -   -   1件:
96
 139   Omeprazole  16件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Clartihromycin, amoxicillin, and omeprazole; Diclofenac + omeprazole; Dimebon + omeprazole; Naproxen 500 mg tablets (pn 200 minus omeprazole); Omeprazole; Omeprazole (uk licensed generic product); Omeprazole 20 mg; Omeprazole 20mg; Omeprazole 20mg bid; Omeprazole 40 mg; Omeprazole 40mg capsule; Omeprazole magnesium; Omeprazole rectally 1mg/kg; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Rifaximin+omeprazole+miralax;   D00455
 D01207
 D05259
 D05261 
 2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   15件:
6,
8,
13,
46,
51,
85,
96,
97,
98,
225,
271,
282,
294,
298,
299
 140   Oprelvekin  3件: Neumega (oprelvekin, interleukin 11, il-11); Oprelvekin; Oprelvekin, interleukin 11, il-11;   D05266   1件: IL11RA   3件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway   2件:
96,
288
 141   Oxygen  9件: Continuous oxygen; Helium / oxygen mixed gas inhalation therapy; Medical air vs oxygen; Medical grade oxygen; Nitric oxide plus oxygen; Oxygen; Oxygen 40 %; Oxygen supplementation; Perfluorinated gas/oxygen mixture;   D00003   -   -   18件:
5,
6,
17,
46,
49,
70,
84,
85,
86,
88,
90,
96,
97,
193,
211,
226,
299,
330
 142   Ozanimod  5件: Ozanimod; Ozanimod 0.5 mg; Ozanimod 1 mg; Ozanimod hydrochloride; Rpc1063 (equivalent to ozanimod hcl);   D10968   5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5   3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway   3件:
13,
96,
97
 143   PF-06651600  1件: Pf-06651600;   -   -   -   3件:
46,
96,
97
 144   PF-06700841  4件: Pf-06700841; Pf-06700841 15 mg; Pf-06700841 30 mg; Pf-06700841 45 mg;   -   -   -   3件:
49,
96,
97
 145   Pancrelipase  9件: Pancrecarb® (pancrelipase); Pancrelipase; Pancrelipase amylase; Pancrelipase delayed release; Pancrelipase delayed release capsule; Pancrelipase microtablets; Pancrelipase with bicarbonate; Pancrelipase/pancreas powder; Viokase 16 (pancrelipase) + nexium;   D05349   -   -   4件:
96,
97,
298,
299
 146   Pancrelipase amylase  1件: Pancrelipase amylase;   -   -   -   4件:
96,
97,
298,
299
 147   Pancrelipase lipase  -  -   -   -   4件:
96,
97,
298,
299
 148   Pancrelipase protease  -  -   -   -   4件:
96,
97,
298,
299
 149   Pectin  1件: Pectin;   D02316   -   -   1件:
96
 150   Pentoxifylline  1件: Pentoxifylline;   D00501   -   -   10件:
26,
56,
84,
93,
96,
113,
220,
222,
296,
298
 151   Phosphate ion  -  -   -   -   29件:
2,
3,
11,
12,
13,
28,
36,
46,
49,
51,
53,
60,
62,
65,
70,
78,
81,
83,
90,
96,
97,
164,
235,
256,
283,
284,
285,
286,
299
 152   Phylloquinone  2件: Phylloquinone; Phylloquinone (vitamin k1);   D00148   -   -   4件:
13,
46,
96,
288
 153   Pioglitazone  6件: Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl;   D00945
 D08378 
 1件: PPARG   9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer   17件:
2,
6,
13,
15,
20,
46,
49,
65,
67,
78,
81,
86,
96,
229,
265,
298,
299
 154   Polaprezinc  1件: Polaprezinc;   D01611   -   -   2件:
96,
97
 155   Polyethylene glycol  3件: 2l polyethylene glycol/ascorbic acid; Polyethylene glycol; Polyethylene glycol 3350;   D03370   -   -   2件:
96,
97
 156   Pomegranate  1件: Pomegranate;   -   -   -   2件:
96,
97
 157   Prasterone  2件: Prasterone; Prasterone (gl701);   D08409   3件: AR, ESR1, ESR2   11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway   6件:
49,
53,
83,
86,
96,
113
 158   Pravastatin  4件: Lonafarnib, zoledronic acid, and pravastatin; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Pravastatin; Pravastatin sodium;   D00893
 D08410 
 1件: HMGCR   4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   9件:
13,
46,
49,
67,
79,
96,
164,
265,
333
 159   Prednisolone  46件: Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroid (prednisolone); Corticosteroid treatment (methylprednisolone or prednisolone); Corticosteroids (prednisone or prednisolone); Etanercept, methotrexate, prednisolone; Glucocorticoid (prednisone or prednisolone); Intravenous methyl prednisolone; Long-circulating liposomal prednisolone; Low dose prednisolone; Medium dose prednisolone; Methotrexate - etanercept - prednisolone arm; Methyl prednisolone; Methylprednisolone or prednisolone; Oral prednisolone; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Peg-liposomal prednisolone sodium phosphate; Prednisolone; Prednisolone & dipyridamole; Prednisolone + mabthera; Prednisolone 1mg tablets; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone 5mg tablet; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisolone and taper; Prednisolone sodium metasulphobenzoate; Prednisolone sodium phosphate; Prednisolone sodium succinate; Prednisolone tablets b.p. 5mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednisone or prednisolone; Prednisone/prednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).;   D00472
 D00980
 D00981
 D00982
 D01239
 D01998
 D02156
 D03301 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   38件:
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300
 160   Prednisone  57件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone);   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   44件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 161   Promethazine  1件: Promethazine;   D00480
 D00494
 D01242
 D03290 
 1件: HRH1   3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction   1件:
96
 162   Prucalopride  2件: Prucalopride; Prucalopride succinate;   D09205   1件: HTR4   4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway   3件:
13,
51,
96
 163   Rabbit  15件: Anti-thymocyte globulin (rabbit); Anti-thymocyte globulin, rabbit; Antithymocyte globulin (rabbit); Antithymocyte immunoglobulin (rabbit); Cyclophosphamide, fludarabine, rabbit atg; Rabbit; Rabbit anti-thymocyte globulin; Rabbit anti-thymocyte globulin (atg); Rabbit antithymocyte globulin; Rabbit antithymoglobulin (atg); Rabbit atg; Rabbit atg, (genzyme); Rabbit atg, cyclosporine, levamisole; Rabbit atg, thymoglobuline (genzyme); Rabbit human t lymphocyte immunoglobulin;   -   -   -   7件:
13,
49,
51,
60,
65,
96,
285
 164   Remestemcel-L  2件: Prochymal (remestemcel-l); Remestemcel-l;   D09719   -   -   2件:
85,
96
 165   Rhamnose  2件: Lactulose/rhamnose solution; Rhamnose;   -   -   -   1件:
96
 166   Ribavirin  1件: Ribavirin;   D00423   -   -   2件:
2,
96
 167   Riboflavin  4件: Cofactor supplementation (thiamine, riboflavin, l-carnitine); Riboflavin; Riboflavin sodium phosphate injection; Riboflavin supplementation;   D00050
 D01622
 D01913 
 -   -   9件:
13,
38,
46,
49,
96,
97,
162,
168,
265
 168   Rifabutin  2件: Rifabutin; Rifabutin, clarithromycin, and clofazimine;   D00424   -   -   1件:
96
 169   Rifaximin  9件: Rifaximin; Rifaximin 550 mg; Rifaximin delayed release (dr); Rifaximin delayed release 400 mg film coated tablet; Rifaximin delayed release tablets; Rifaximin eir; Rifaximin oral tablet; Rifaximin+omeprazole+miralax; Rifaximin-eir;   D02554   -   -   7件:
6,
65,
94,
96,
97,
99,
296
 170   Risankizumab  4件: Risankizumab; Risankizumab (genetical recombination); Risankizumab iv; Risankizumab sc;   D11052   1件: IL23A   9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis   4件:
37,
96,
97,
271
 171   Risedronic acid  1件: Risedronic acid;   D00942
 D03234
 D08484 
 1件: FDPS   4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis   7件:
46,
66,
93,
95,
96,
113,
274
 172   Rituximab  52件: Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Administration of rituximab and methylprednisolone; Alemtuzumab and rituximab; Alemtuzumab, rituximab; Bendamustine, rituximab; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Combined plasma exchange (pex), rituximab, and corticosteroids; Dexamethasone and rituximab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Immunosuppressive treatment (eg, rituximab); Individualized dose of rituximab; Intravenous rituximab; Mabthera (rituximab); Mabthera or biosimilar rituximab; Mabthera or biosimilar rituximab product; Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Rhtpo in combination with rituximab; Rituxan (inn: rituximab), brand name in the united states; Rituxan (rituximab); Rituxan® (rituximab); Rituximab; Rituximab (anti-cd20); Rituximab (arm a); Rituximab (arm b); Rituximab (mabthera® or rituxan®).; Rituximab (mabthera®); Rituximab (rituxan); Rituximab (rtx) and azathioprine (aza); Rituximab - mabthera; Rituximab 1g iv; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab and cyclophosphamide iv; Rituximab combined with omalizumab; Rituximab infusion; Rituximab it; Rituximab iv; Rituximab mabthera; Rituximab or rituximab hyaluronidase human; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rituximab/ mabthera; Sait101 (proposed rituximab biosimilar); Standard dose of rituximab; The standard steroid treatment, plasma exchange and rituximab;   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331
 173   Rosuvastatin  6件: Calcium rosuvastatin; Crestor tablets (calcium rosuvastatin) film-coated tablets; Rosuvastatin; Rosuvastatin 10 mg; Rosuvastatin 20mg; Rosuvastatin calcium;   D01915
 D08492 
 1件: HMGCR   4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   8件:
6,
46,
49,
51,
79,
96,
271,
299
 174   SC12267  2件: Sc12267; Sc12267 (4sc-101);   -   -   -   3件:
46,